Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Inflammatory bowel disease during active flares GI side effects can be hard to distinguish from disease activity, and tolerability can be lower during flares
Key Milestones Timeline Eli Lillys Strategic Context Retatrutides development occurs within Eli Lillys broader metabolic disease portfolio, which also includes tirzepatide (approved as Mounjaro for type 2 diabetes and Zepbound for obesity) and orforglipron (an oral GLP-1R agonist in Phase 3 development)
In comparison, other GLP-1 agonists have also been beneficial, but some patients voice a distinct preference for semaglutide due to its once-weekly dosing convenience
[4] [1] The most common injection site reactions include: Erythema (redness) : Localised redness surrounding the injection site, typically appearing within minutes to hours after administration Pruritus (itching) : Mild to moderate itching at or around the injection site Swelling or induration : Raised, firm areas of skin that may persist for several hours Pain or tenderness : Discomfort ranging from mild sensitivity to more pronounced soreness Bruising (ecchymosis) : Small haematomas resulting from minor blood vessel trauma during injection Most injection site reactions develop within 24 hours of administration and resolve within 23 days without specific treatment
Therefore, until regulators complete their review, readers should describe eloralintide accurately as an investigational peptide drug rather than an approved obesity treatment
